results of therapy for hepatocellular carcinoma between 1982 and 1994 in gastrtenterology Division I
An analysis of a total of 461 patients with hepatocellular carcinoma (ＨＣＣ) who had undergone various therapies between 1982 and 1994 was made to investigate prognosis. The cumulative 1-，3-，5-year survival rates in 312 cases undergoing transcather arterial embolization (ＴＡＥ) were 61.3％, 20.6％, and 8％, respectively. Those of percutaneous ethanol injection (ＰＥＩ) in 126 cases were 74.9％, 35.3％, and 8％, respectively. In 23 cases on whom hepatectomy (ＯＰＥ) was performed, the survival rates were 78.3％, 50.8％ and 41.6％. The frequency of repetition of therapy in the same patient was 1-5 times (1.6 times on average) for ＴＡＥ and １-22 times (5.6 times on average) for PEI. The intervals of repetition within one year were 75.0％ and 78.6％ for ＴＡＥ and ＰＥＩ, respectively. Among the patients who underwent ＯＰＥ, 10 out of 23 (43.5％) survived five years, of whom only four cases (17.4％) are still alive without recurrence. (Accepted on July 17, 1997) Kawasaki Igakkaishi 23(2) : 81-86, 1997
